Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2011

View Archived Issues

AMP-224 boosts BCG-induced immune responses against bladder cancer

Preclinical activity of asthma candidate RV-1088 described at American Thoracic Society meeting

AlloStem Therapeutics designs novel MEK inhibitors

GlaxoSmithKline prepares new agents against hepatitis C virus

Phase I trials show AIC-316 is safe and well tolerated

Post hoc analysis supports selegiline transdermal system for treatment of depression

Wnt signaling inhibition has therapeutic activity in choroidal neovascularization

New anticancer antofine and cryptopleurine derivatives disclosed

Grindeks presents new agent for myocardial infarction

Phase II study begins for BKM-120 in recurrent glioblastoma

Gilead Sciences patents novel Toll-like receptor agonists

Ono Pharmaceutical recaps events of fourth quarter fiscal year 2011

ACADIA Pharmaceuticals receives NIH grant to develop new ER-beta agonists

BIBF-1120 moves to phase III in idiopathic pulmonary fibrosis

Oxford BioMedica presents update on drug pipeline

Ablynx discloses proof-of-concept phase II data on ozoralizumab in rheumatoid arthritis

Sprix analgesic nasal spray launched in U.S.

Merck & Co. and Roche enter into nonexclusive agreements for hepatitis C therapies

Histogenics acquires ProChon Biotech

CITN selects recombinant IL-7 CYT-107 for clinical testing at network institutions

Anacor initiates dosing in phase II trial of AN-2728 and AN-2898 in atopic dermatitis

ERYtech and Teva sign long-term agreement on Graspa

Quest Diagnostics acquires Celera

Shire to acquire Advanced BioHealing

CryoLife acquires Cardiogenesis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...